AstraZeneca plc (LON:AZN) insider Marc Dunoyer acquired 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The stock was acquired at an average cost of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82).
AZN stock opened at GBX 5,835 ($76.24) on Thursday. AstraZeneca plc has a 12-month low of GBX 5,110 ($66.77) and a 12-month high of GBX 6,540 ($85.46). The company has a quick ratio of 0.57, a current ratio of 0.75 and a debt-to-equity ratio of 179.66. The stock has a market cap of $76.54 billion and a price-to-earnings ratio of 30.71.
A number of equities research analysts have recently commented on AZN shares. Barclays lifted their price objective on AstraZeneca from GBX 6,800 ($88.85) to GBX 7,000 ($91.47) and gave the company an “overweight” rating in a research report on Monday, April 1st. Goldman Sachs Group set a GBX 5,000 ($65.33) price objective on AstraZeneca and gave the company a “sell” rating in a research report on Thursday, April 11th. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Wednesday, March 20th. UBS Group reaffirmed a “sell” rating and issued a GBX 5,400 ($70.56) price objective on shares of AstraZeneca in a research report on Tuesday, April 23rd. Finally, JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price objective on AstraZeneca and gave the company a “buy” rating in a research report on Tuesday, January 29th. Three analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 6,367.70 ($83.21).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Put Option